The Chinese life sciences firm Hengrui Pharma will establish a research and development center in Zurich. According to a press release issued by Steiner AG, the group has decided on Manufakt8048 for its new location, a business park concept which was recently opened this summer and developed by the general contractor. Here, Hengrui Europe Biosciences AG will rent premises covering a total area of roughly 1,260 square meters, the press release explains.
“Greater Zurich is the ideal hub for our company's technical development but also to further advance in the field of life sciences”, comments Slavoljub Milosevic, Vice President, Head of European Research Center, Biologic Drug Discovery at Hengrui Europe Biosciences AG. He adds: “The wealth of talent as well as the high concentration of innovative companies, universities and research institutions have strengthened our decision to establish our company here”.
Hengrui is already represented in Switzerland: Hengrui Europe Therapeutics AG, its European headquarters, is based in Basel.
According to information from the company itself, Hengrui specializes in the development of oncological and surgical drugs, among other things. In May 2018, the company was one of seven Chinese firms to be included on a Forbes list of the world’s most innovative companies.